Table 1.

Patient disposition (safety set).

Patients, n (%)	Vildagliptin	Liraglutide	Total
Treated*	60 (100.0)	62 (100.0)	62 (100.0)
Completed§	25 (41.7)	28 (45.2)	53 (85.5)
Discontinued§	3 (5.0)	6 (9.7)	9 (14.5)
Main cause of discontinuation§
Unsatisfactory therapeutic effect	3 (5.0)	0	3 (4.8)
Patient withdrew consent	0	3 (4.8)	3 (4.8)
Adverse event	0	1 (1.6%)§	1 (1.6)
Abnormal laboratory value	0	1 (1.6%)	1 (1.6)
Therapy no longer required	0	1 (1.6%)	1 (1.6)

^*Refers to the number of patients who received each treatment at least once.

^§Refers to the last treatment before completion or discontinuation; the patient who discontinued due to an adverse event discontinued only period I but completed period II.

Safety set consisted of all patients who received at least one dose of the study medication during at least one study period and had at least one safety assessment after baseline.